Assessment of feasibility and safety of the addition of ZD6474 (Zactima) [vandetanib] to carboplatin and paclitaxel administered neo-adjuvantly in stage IB, II and T3, N1 non-small cell lung cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Vandetanib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Apr 2007 New trial record.